SanatelaTM Matrix is an advanced biomaterial tissue that promises to profoundly improve the screening of new and existing treatments against deadly cancer stem cells. The product revolutionizes the way cancer treatments are developed and targeted for individual patients.

 

“We take a leukemia sample, culture the cells on the Matrix in our lab, then determine which drug is most effective. It’s individualized therapy, with the goal of making all patients with leukemia potentially cured.”

Dr. Omar S. Aljitawi
Matrix Co-Inventor

Join the growing list of select research hospitals and cancer centers in performing clinical research studies on this exciting new technology breakthrough.

Improving leukemia treatment is just one of many ways the Sanatela Matrix is making medical advances.
The Matrix tissue may potentially be a vast improvement over existing wound dressings available on the market today.

The Matrix, a natural 3D biological tissue which resembles gauze, is made from a material in human umbilical cords called Wharton’s Jelly, which is decellularized and bioengineered to attract and isolate cancer cells from a patient’s blood sample.

Once in the Matrix, doctors can safely test a range of cancer treatments in the lab and identify the ones that are fully effective in treating, and hopefully curing, leukemia patients.

“As an oncologist who makes treatment decisions every day, the ability to test all the therapies and options and create a treatment plan in the lab – before I administer it to my patient – will be a major improvement,” says Dr. Aljitawi.

“Oncologists already have a number of readily available therapies to treat most cancers,” says Sanatela Founder and Professor Michael Crowley, “but the challenge has always been to figure out which of the many treatment options will potentially not only target, but will also kill all of the cancer stem cells. Our new Matrix product takes the guesswork out of it.”

Sanatela is currently looking to build a major clean lab facility to support the expected demand for Sanatela’s full range of tissue products. Mr. Crowley is exploring sites in New York, Texas and other states that provide incentives to companies that create good jobs in the region. It plans to have the first Matrix products on the market by October or November 2019.

Leukemia cells adhering to the Matrix in vitro.

“We believe the Matrix will have a decided advantage over other products currently on the market,” says Dr. Hani A. Awad, Sanatela Chief Bioengineering Officer. “It could be used for wound dressings and other situations that require the regeneration of tissue to replace a missing part of bone or skin.“

 

Dr. Hani A. Awad
Matrix Co-Inventor

Share This